CM313 + lenalidomide + dexamethasone

This is a **combination therapy** consisting of CM313, lenalidomide, and dexamethasone. - **CM313** is a novel humanized monoclonal antibody directed against CD38, with a unique complementarity-determining region providing higher affinity for CD38 than other anti-CD38 antibodies like daratumumab. It induces tumor cell death via **antibody-dependent cellular cytotoxicity (ADCC)**, **complement-dependent cytotoxicity (CDC)**, **antibody-dependent cellular phagocytosis (ADCP)**, and inhibition of CD38 enzymatic activity. - **Lenalidomide** is an immunomodulatory agent that enhances immune function and has direct and indirect antitumor effects, including upregulation of CD38 on myeloma cells and synergy when combined with monoclonal antibodies. - **Dexamethasone** is a synthetic glucocorticoid with broad anti-inflammatory and immunosuppressant properties, frequently used in multiple myeloma regimens to reduce inflammation and support anti-cancer treatments. This regimen is primarily studied and developed for **relapsed/refractory multiple myeloma** and has shown robust preclinical activity, with ongoing clinical trials.

Other names

CM313 + RdCM313 plus lenalidomide and dexamethasoneCM-313 plus lenalidomide and dexamethasoneCM 313 plus lenalidomide and dexamethasone